Prof. Dr. med. Roland Schmieder

Medizinische Fakultät Professur für Innere Medizin (Nephrologie)

ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE (2022) Bosch A, Poglitsch M, Kannenkeril D, Ott C, Pietschner R, Striepe K, Schiffer M, Schmieder R Journal article IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES (2022) Kannenkeril D, Ott C, Bosch A, Striepe K, Pietschner R, Schiffer M, Schmieder R Journal article CLINICAL EVENT REDUCTIONS IN HIGH-RISK HYPERTENSION PATIENTS TREATED WITH RENAL DENERVATION: 10-YEAR PROJECTIONS BASED ON 3-YEAR FOLLOW-UP FROM THE GLOBAL SYMPLICITY REGISTRY (2022) Esler M, Cao K, Lobo M, Sharp AS, Kandzari DE, Mancia G, Böhm M, et al. Journal article DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE (2022) Pietschner R, Kolwelter J, Bosch A, Striepe K, Kannenkeril D, Ott C, Schiffer M, et al. Conference contribution ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE (2022) Bosch A, Poglitsch M, Kannenkeril D, Ott C, Pietschner R, Striepe K, Schiffer M, Schmieder R Conference contribution Renal denervation in patients with chronic kidney disease: current evidence and future perspectives (2022) Schmieder R Journal article, Review article High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study (2022) Silbernagel G, Duarte K, Sadiku S, Fauler G, Maerz W, Schmieder R, Jardine AG, et al. Journal article 10-YEAR CLINICAL EVENTS AVOIDED IN DIABETIC AND CHRONIC KIDNEY DISEASE HYPERTENSION PATIENTS TREATED WITH RADIOFREQUENCY RENAL DENERVATION: PROJECTIONS BASED ON 3-YEAR DATA FROM THE GLOBAL SYMPLICITY REGISTRY (2022) Schmieder R, Cao K, Esler M, Kandzari D, Lobo M, Sharp A, Mancia G, et al. Conference contribution Reduction of Clinical Events in High-Risk Hypertension Patients Treated With Renal Denervation: A Modeled Estimate From 36-Month Global SYMPLICTY Registry Data (2022) Schlaich M, Pietzsch JB, Mahfoud F, Wiliams B, Mancia G, Narkiewicz K, Ruilope L, et al. Conference contribution Physician Preferences for Recommending Renal Denervation to Hypertensive Patients Is Influenced by Patients' Antihypertensive Medication Nonadherence Due to Medication Side Effects (2022) Wang TD, Schmieder R, Kandzari DE, Lee YH, Haro CF, Pathak A Conference contribution